Groupe Hospitalier Pitie-Salpetriere
aphp.frTotal trials
63
Active
1
Phase 3
3
Total enrollment
1,996,055
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| arm A - angiotensin converting enzyme inhibitors | — | — | — | — | — | 1 | |
| arm B - calcium channel blockers | — | — | — | — | — | 1 | |
| arm R - angiotensin receptor blockers ARB | — | — | — | — | — | 1 |
Next readouts
- 2024-08-01
Top conditions
- Cancer4
- Myocarditis4
- Cardiac Complication3
- Pneumonia3
- Heart Diseases2
- Systemic Lupus Erythematosus2
- Neuropathy2
- Parkinson's Disease2
Frequently asked questions about Groupe Hospitalier Pitie-Salpetriere
- How many clinical trials does Groupe Hospitalier Pitie-Salpetriere have on ClinicalTrials.gov?
- Groupe Hospitalier Pitie-Salpetriere is listed as the lead sponsor on 63 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Groupe Hospitalier Pitie-Salpetriere's trials are in Phase 3?
- 3 of Groupe Hospitalier Pitie-Salpetriere's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Groupe Hospitalier Pitie-Salpetriere focus on?
- Groupe Hospitalier Pitie-Salpetriere's most-studied conditions on ClinicalTrials.gov are Cancer, Myocarditis, Cardiac Complication, Pneumonia, Heart Diseases.
- When are Groupe Hospitalier Pitie-Salpetriere's next clinical trial readouts?
- Groupe Hospitalier Pitie-Salpetriere has 1 upcoming primary-completion readout tracked here; the soonest is “Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension”, expected around 2024-08-01.